Stay updated on Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page.

Latest updates to the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page indicates a site-wide revision update to v3.4.2 and removal of the prior government-funding notice; these changes are maintenance-related and do not alter any trial details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedA site-wide notice about government funding lapse and NIH operating status was added, and the page revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedAdditions include a 'Show glossary' option and new metadata entries such as 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0'; deletions remove older items like 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and the prior 'Revision: v3.3.4'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check35 days agoChange DetectedDeleted PDF links for the Statistical Analysis Plan (9.25 MB, 2024-07-31) and Study Protocol (3.5 MB, 2023-12-07), along with related documents and provider information.SummaryDifference19%

- Check42 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed, updating the page version label.SummaryDifference0.0%

- Check63 days agoChange DetectedAdded a consolidated Locations section listing participating sites by state (Arizona, Arkansas, California, Colorado, Florida, Louisiana, North Carolina, Oklahoma, Rhode Island, Tennessee, Texas) and removed the previous per-state location subsections. This update improves visibility of where the study is conducted.SummaryDifference1%

Stay in the know with updates to Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page.